Wisconsin Brain Donor Program
Launched by UNIVERSITY OF WISCONSIN, MADISON · Jan 2, 2008
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The Wisconsin Brain Donor Program (WBDP) of the University of Wisconsin-Madison School of Medicine and Public Health is considered an investigator-initiated project. It was first established in 1995 to promote teaching and research in neurodegenerative diseases. In 2009 the WBDP aligned itself with the research goals of the Wisconsin Alzheimer's Disease Research Center (Wisconsin ADRC) in order to more effectively serve the research community. As a result, the WBDP is part of a nationwide network of ADC/ADRC's (Alzheimer's Disease Centers/Alzheimer's Disease Research Centers), funded by the...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Is aged 18 years or older
- * Falls into one of the following categories:
- • Current or previous study participants involved in the ADRC Clinical Core, WRAP study, or other select ADRC-affiliated studies, or donors of special circumstance, including healthy controls, if approved on a case-by-case basis by the WBDP PI. Please note, ADRC-affiliated studies are not inclusive of ADRC-affiliated industry-sponsored studies.
- • Is a parent of either an ADRC Clinical Core or WRAP study participant, or is a spouse of a WRAP study participant.
- Exclusion Criteria:
- • VA research subjects
- * Subjects with a medical condition/disease that would exclude them from the spectrum of utility/interest to researchers as determined by a WBDP Neuropathologist:
- • 1. Persons with Hepatitis B or C
- • 2. Severe Traumatic Brain Injury
- • 3. Positive CJD diagnosis
- • 4. Persons with HIV/AIDS
- • 5. Persons with brain tumors or blood clots that affect neurologic status, therefore creating a problem between diagnosing AD status and healthy status
- • 6. Cancer that has metastasized to the brain
- • 7. Radiation treatment to the head
- • 8. Other infectious diseases that would be hazardous to staff handling the tissue
- • 9. Prolonged ventilator dependency prior to death as determined by the Neuropathologist
- • Subjects who lack capacity to provide informed consent with no activated Power of Attorney (POA) for Healthcare, activated POA for Research, or legal guardianship (if not near death), or (if at or near death) have no spouse, parent, relative or friend willing/able to complete consent and other donation paperwork.
- • Subjects who otherwise have incomplete history or incomplete donation paperwork before a recovery can begin.
- • Subjects younger than 18 years of age.
- • An expected post-mortem interval (PMI) of greater than 16 hours for non-ADRC or non-WRAP participants. PMI is the time between death and the anticipated time of brain removal at autopsy. Families and recovery agencies are made aware of this time constraint when consenting for the recovery process. If a patient becomes ineligible due to PMI, the family and funeral home will be notified immediately. Diversions from this exclusion can be made by a WBDP PI or Co-PI.
- • Medical conditions that would put researchers at risk.
- • Other contingencies, as determined by the PI, that make enrollment impractical or unsafe.
- • Note: It is anticipated, based upon the younger age of our study cohorts, that significant time may pass between WBDP registration and actual donation. The inclusion/exclusion criteria will be reviewed and applied at time of donation. As a result, donated tissue found to be unsuitable may be removed from the post-mortem tissue and biosamples collection.
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Shahriar Salamat, MD PHD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials